As filed with the Securities and Exchange Commission on  June 14, 2005

Registration No. 333-79241

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549


POST-EFFECTIVE AMENDMENT NO. 2

TO

FORM S-8

REGISTRATION STATEMENT UNDER
THE SECURITIES ACT OF 1933


MEDIMMUNE, INC.

(Exact name of registrant as specified in its charter)

One MedImmune Way

 

DELAWARE

Gaithersburg, Maryland 20878

55-1555759

(State or other jurisdiction of incorporation or organization)

(Address of Principal Executive Offices) (Zip Code)

(I.R.S. Employer Identification No.)

 


1999 Stock Option Plan

(Full Title of the Plan)


David M. Mott

Chief Executive Officer, President and Vice Chairman
MedImmune, Inc.
One MedImmune Way
Gaithersburg, Maryland 20878

(Name and address of agent for service)


Telephone number, including area code, of agent for service:

(301) 398-0000

This Post-effective Amendment No. 2 is being filed with the Securities and Exchange Commission by the Registrant, in order to de-register 2,000,000 shares of the Registrant’s common stock, par value $.01 per share, covered under the Company’s 1999 Stock Option Plan that are not subject to outstanding stock options. Such shares were registered under a Registration Statement on Form S-8 (Registration No. 333-79241) which was filed on May 25, 1999, as modified pursuant to General Instruction E of Form S-8 by Registration Statements on Form S-8 filed on May 8, 2001 (Registration No. 333-60408), June 13, 2002 (Registration No. 333-90402) and May 27, 2003 (Registration No. 333-105578). The Registrant has carried forward all of the deregistered shares to a Registration Statement on Form S-8 covering the Registrant’s 2004 Stock Incentive Plan.

 




SIGNATURES

The Registrant. Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Post-effective Amendment No. 2 to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Gaithersburg, State of Maryland, on the 14th day of June, 2005.

 

MEDIMMUNE, INC.

 

By:

/s/ DAVID M. MOTT

 

 

 

David M. Mott

 

 

Chief Executive Officer, President and Vice Chairman

 

Pursuant to the requirements of the Securities Act of 1933, this Post-effective Amendment No. 2 has been signed by the following persons in the capacities and on the dates indicated.

Signature

 

 

 

Title

 

 

 

Date

 

 

/s/ WAYNE T. HOCKMEYER, PH.D.

 

Chairman of the Board

 

June 14, 2005

Wayne T. Hockmeyer, Ph.D.

 

 

 

 

/s/ DAVID M. MOTT

 

Chief Executive Officer, President and Vice

 

June 14, 2005

David M. Mott

 

Chairman of the Board (Principal Executive Officer)

 

 

/s/ DAVID BALTIMORE, PH. D.

 

Director

 

June 14, 2005

David Baltimore, Ph. D.

 

 

 

 

/s/ M. JAMES BARRETT, PH.D.

 

Director

 

June 14, 2005

M. James Barrett, Ph.D.

 

 

 

 

/s/ JAMES H. CAVANAUGH, PH.D.

 

Director

 

June 14, 2005

James H. Cavanaugh, Ph.D.

 

 

 

 

/s/ BARBARA HACKMAN FRANKLIN

 

Director

 

June 14, 2005

Barbara Hackman Franklin

 

 

/s/ GORDON S. MACKLIN

 

Director

 

June 14, 2005

Gordon S. Macklin

 

 

 

 

/s/ GEORGE M. MILNE, JR., PH.D.

 

Director

 

June 14, 2005

George M. Milne, Jr., Ph.D.

 

 

 

 

/s/ ELIZABETH WYATT

 

Director

 

June 14, 2005

Elizabeth Wyatt

 

 

 

 

/s/ LOTA S. ZOTH

 

Senior Vice President and Chief Financial

 

June 14, 2005

Lota S. Zoth

 

Officer (Principal Financial Officer)

 

 

/s/ MARK E. SPRING

 

Vice President, Finance and Controller

 

June 14, 2005

Mark E. Spring

 

(Principal Accounting Officer)

 

 

 

 

2